A Smartphone App to Improve Medication Adherence in Patients With Type 2 Diabetes in Asia: Feasibility Randomized Controlled Trial
BackgroundThe efficacy of smartphone apps for improving medication adherence in type 2 diabetes is not well studied in Asian populations. ObjectiveThis study aimed to determine the feasibility, acceptability, and clinical outcomes of using a smartphone app to improve medication adherence...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JMIR Publications
2019-09-01
|
| Series: | JMIR mHealth and uHealth |
| Online Access: | http://mhealth.jmir.org/2019/9/e14914/ |
| _version_ | 1819278970688897024 |
|---|---|
| author | Huang, Zhilian Tan, Eberta Lum, Elaine Sloot, Peter Boehm, Bernhard Otto Car, Josip |
| author_facet | Huang, Zhilian Tan, Eberta Lum, Elaine Sloot, Peter Boehm, Bernhard Otto Car, Josip |
| author_sort | Huang, Zhilian |
| collection | DOAJ |
| description | BackgroundThe efficacy of smartphone apps for improving medication adherence in type 2 diabetes is not well studied in Asian populations.
ObjectiveThis study aimed to determine the feasibility, acceptability, and clinical outcomes of using a smartphone app to improve medication adherence in a multiethnic Asian population with type 2 diabetes.
MethodsWe block randomized 51 nonadherent and digitally literate patients with type 2 diabetes between the ages of 21 and 75 years into two treatment arms (control: usual care; intervention: usual care+Medisafe app) and followed them up for 12 weeks. Recruitment occurred at a public tertiary diabetes specialist outpatient center in Singapore. The intervention group received email reminders to complete online surveys monthly, while the control group only received an email reminder(s) at the end of the study. Barriers to medication adherence and self-appraisal of diabetes were assessed using the Adherence Starts with Knowledge-12 (ASK-12) and Appraisal of Diabetes Scale (ADS) questionnaires at baseline and poststudy in both groups. Perception toward medication adherence and app usage, attitude, and satisfaction were assessed in the intervention group during and after the follow-up period. Sociodemographic data were collected at baseline. Clinical data (ie, hemoglobin A1c, body mass index, low-density lipoprotein, high-density lipoprotein, and total cholesterol levels) were extracted from patients’ electronic medical records.
ResultsA total of 51 (intervention group: 25 [49%]; control group: 26 [51%]) participants were randomized, of which 41 (intervention group: 22 [88.0%]; control group: 19 [73.1%]) completed the poststudy survey. The baseline-adjusted poststudy ASK-12 score was significantly lower in the intervention group than in the control group (mean difference: 4.7, P=.01). No changes were observed in the clinical outcomes. The average 12-week medication adherence rate of participants tracked by the app was between 38.3% and 100% in the intervention group. The majority (>80%) of the participants agreed that the app was easy to use and made them more adherent to their medication.
ConclusionsOur feasibility study showed that among medication-nonadherent patients with type 2 diabetes, a smartphone app intervention was acceptable, improved awareness of medication adherence, and reduced self-reported barriers to medication adherence, but did not improve clinical outcomes in a developed Asian setting. |
| first_indexed | 2024-12-24T00:20:28Z |
| format | Article |
| id | doaj.art-e850a55e82464dbd9aba632fcdc23036 |
| institution | Directory Open Access Journal |
| issn | 2291-5222 |
| language | English |
| last_indexed | 2024-12-24T00:20:28Z |
| publishDate | 2019-09-01 |
| publisher | JMIR Publications |
| record_format | Article |
| series | JMIR mHealth and uHealth |
| spelling | doaj.art-e850a55e82464dbd9aba632fcdc230362022-12-21T17:24:37ZengJMIR PublicationsJMIR mHealth and uHealth2291-52222019-09-0179e1491410.2196/14914A Smartphone App to Improve Medication Adherence in Patients With Type 2 Diabetes in Asia: Feasibility Randomized Controlled TrialHuang, ZhilianTan, EbertaLum, ElaineSloot, PeterBoehm, Bernhard OttoCar, JosipBackgroundThe efficacy of smartphone apps for improving medication adherence in type 2 diabetes is not well studied in Asian populations. ObjectiveThis study aimed to determine the feasibility, acceptability, and clinical outcomes of using a smartphone app to improve medication adherence in a multiethnic Asian population with type 2 diabetes. MethodsWe block randomized 51 nonadherent and digitally literate patients with type 2 diabetes between the ages of 21 and 75 years into two treatment arms (control: usual care; intervention: usual care+Medisafe app) and followed them up for 12 weeks. Recruitment occurred at a public tertiary diabetes specialist outpatient center in Singapore. The intervention group received email reminders to complete online surveys monthly, while the control group only received an email reminder(s) at the end of the study. Barriers to medication adherence and self-appraisal of diabetes were assessed using the Adherence Starts with Knowledge-12 (ASK-12) and Appraisal of Diabetes Scale (ADS) questionnaires at baseline and poststudy in both groups. Perception toward medication adherence and app usage, attitude, and satisfaction were assessed in the intervention group during and after the follow-up period. Sociodemographic data were collected at baseline. Clinical data (ie, hemoglobin A1c, body mass index, low-density lipoprotein, high-density lipoprotein, and total cholesterol levels) were extracted from patients’ electronic medical records. ResultsA total of 51 (intervention group: 25 [49%]; control group: 26 [51%]) participants were randomized, of which 41 (intervention group: 22 [88.0%]; control group: 19 [73.1%]) completed the poststudy survey. The baseline-adjusted poststudy ASK-12 score was significantly lower in the intervention group than in the control group (mean difference: 4.7, P=.01). No changes were observed in the clinical outcomes. The average 12-week medication adherence rate of participants tracked by the app was between 38.3% and 100% in the intervention group. The majority (>80%) of the participants agreed that the app was easy to use and made them more adherent to their medication. ConclusionsOur feasibility study showed that among medication-nonadherent patients with type 2 diabetes, a smartphone app intervention was acceptable, improved awareness of medication adherence, and reduced self-reported barriers to medication adherence, but did not improve clinical outcomes in a developed Asian setting.http://mhealth.jmir.org/2019/9/e14914/ |
| spellingShingle | Huang, Zhilian Tan, Eberta Lum, Elaine Sloot, Peter Boehm, Bernhard Otto Car, Josip A Smartphone App to Improve Medication Adherence in Patients With Type 2 Diabetes in Asia: Feasibility Randomized Controlled Trial JMIR mHealth and uHealth |
| title | A Smartphone App to Improve Medication Adherence in Patients With Type 2 Diabetes in Asia: Feasibility Randomized Controlled Trial |
| title_full | A Smartphone App to Improve Medication Adherence in Patients With Type 2 Diabetes in Asia: Feasibility Randomized Controlled Trial |
| title_fullStr | A Smartphone App to Improve Medication Adherence in Patients With Type 2 Diabetes in Asia: Feasibility Randomized Controlled Trial |
| title_full_unstemmed | A Smartphone App to Improve Medication Adherence in Patients With Type 2 Diabetes in Asia: Feasibility Randomized Controlled Trial |
| title_short | A Smartphone App to Improve Medication Adherence in Patients With Type 2 Diabetes in Asia: Feasibility Randomized Controlled Trial |
| title_sort | smartphone app to improve medication adherence in patients with type 2 diabetes in asia feasibility randomized controlled trial |
| url | http://mhealth.jmir.org/2019/9/e14914/ |
| work_keys_str_mv | AT huangzhilian asmartphoneapptoimprovemedicationadherenceinpatientswithtype2diabetesinasiafeasibilityrandomizedcontrolledtrial AT taneberta asmartphoneapptoimprovemedicationadherenceinpatientswithtype2diabetesinasiafeasibilityrandomizedcontrolledtrial AT lumelaine asmartphoneapptoimprovemedicationadherenceinpatientswithtype2diabetesinasiafeasibilityrandomizedcontrolledtrial AT slootpeter asmartphoneapptoimprovemedicationadherenceinpatientswithtype2diabetesinasiafeasibilityrandomizedcontrolledtrial AT boehmbernhardotto asmartphoneapptoimprovemedicationadherenceinpatientswithtype2diabetesinasiafeasibilityrandomizedcontrolledtrial AT carjosip asmartphoneapptoimprovemedicationadherenceinpatientswithtype2diabetesinasiafeasibilityrandomizedcontrolledtrial AT huangzhilian smartphoneapptoimprovemedicationadherenceinpatientswithtype2diabetesinasiafeasibilityrandomizedcontrolledtrial AT taneberta smartphoneapptoimprovemedicationadherenceinpatientswithtype2diabetesinasiafeasibilityrandomizedcontrolledtrial AT lumelaine smartphoneapptoimprovemedicationadherenceinpatientswithtype2diabetesinasiafeasibilityrandomizedcontrolledtrial AT slootpeter smartphoneapptoimprovemedicationadherenceinpatientswithtype2diabetesinasiafeasibilityrandomizedcontrolledtrial AT boehmbernhardotto smartphoneapptoimprovemedicationadherenceinpatientswithtype2diabetesinasiafeasibilityrandomizedcontrolledtrial AT carjosip smartphoneapptoimprovemedicationadherenceinpatientswithtype2diabetesinasiafeasibilityrandomizedcontrolledtrial |